DrugPatentWatch Database Preview

OTEZLA Drug Profile

« Back to Dashboard

When do Otezla patents expire, and when can generic versions of Otezla launch?

Otezla is a drug marketed by Celgene Corp and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and three patent family members in twenty-two countries.

The generic ingredient in OTEZLA is apremilast. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the apremilast profile page.

Summary for OTEZLA

International Patents:	103
US Patents:	12
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	58
Clinical Trials:	26
Patent Applications:	72
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for OTEZLA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OTEZLA
DailyMed Link:	OTEZLA at DailyMed

Generic Entry Opportunity Date for OTEZLA

NDA:

205437

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OTEZLA

Drug Class	Phosphodiesterase 4 Inhibitor
Mechanism of Action	Phosphodiesterase 4 Inhibitors

Synonyms for OTEZLA

(+)-N-(2-((1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4-yl)acetamide

(S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione(Apremilast)

(S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide

(S)-N-{2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide

608141-41-9

666854-78-0

AB0093139

AC-27650

Acetamide, N-(2-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)- 2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)-

AJ-84147

AK151389

AKOS016339660

AOB87775

Apremilast

Apremilast (CC-10004)

Apremilast (JAN/USAN)

Apremilast [USAN:INN]

Apremilast/CC 10004/

apremilastum

BC600507

BCP0726000109

BCP9000311

BDBM50248919

C22H24N2O7S

cas:608141-41-9;Apremilast

CC 10004

CC-10004

CC10004

CHEBI:78540

CHEMBL514800

CS-0671

D07ESC

D08860

DB05676

EX-A336

FK-0727

FT-0700081

GTPL7372

HE224053

HSDB 8221

HY-12085

IMOZEMNVLZVGJZ-QGZVFWFLSA-N

KB-74720

MFCD18782607

MolPort-023-219-158

N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide

N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

Otezla (TN)

QCR-202

S-7765

s8034

SC-95443

SCHEMBL302992

UNII-N5UK68MGDZ component IMOZEMNVLZVGJZ-QGZVFWFLSA-N

UNII-UP7QBP99PN

UP7QBP99PN

Y0437

ZINC30691736

US Patents and Regulatory Information for OTEZLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014		RX	Yes	No
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014		RX	Yes	No
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No

Expired US Patents for OTEZLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014

Paragraph IV (Patent) Challenges for OTEZLA

Drugname	Dosage	Strength	RLD	Date
	Tablets	10 mg, 20 mg and30 mg

International Patents for OTEZLA

Country	Document Number	Estimated Expiration
Hong Kong	1215671
Portugal	2420490
China	1965823
Denmark	1485087
Japan	2010106033
South Korea	20120024938
China	100427085